Get the Stockscreener App
4.00
0.50%
0.02
Onkure Therapeutics Inc stock is traded at $4.00, with a volume of 176.13K.
It is up +0.50% in the last 24 hours and up +47.60% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. Its flagship program is OKI-219, a selective PI3KαH1047R inhibitor. The Company operates in one operating segment: clinical research.
See More
Previous Close:
$3.98
Open:
$4
24h Volume:
176.13K
Relative Volume:
1.37
Market Cap:
$54.69M
Revenue:
-
Net Income/Loss:
$-59.52M
P/E Ratio:
-0.9081
EPS:
-4.4049
Net Cash Flow:
$-51.87M
1W Performance:
-0.25%
1M Performance:
+47.60%
6M Performance:
+57.48%
1Y Performance:
-16.32%
1-Day Range:
$3.60
$4.10
1-Week Range:
$3.60
$4.75
52-Week Range:
$1.70
$4.90
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.00 | 54.69M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March - MarketBeat
OnKure Therapeutics CFO Leverone sells $1.2k in shares - Investing.com UK
OnKure Therapeutics CFO Leverone sells $1.2k in shares By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock - Investing.com
If You Invested $1,000 in OnKure Therapeutics (OKUR) - Stock Titan
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-19 04:03:55 - baoquankhu1.vn
OnKure reports nearly $60M cash on hand as drug trials continue - BizWest
HC Wainwright Has Positive Forecast for OKUR Q1 Earnings - MarketBeat
OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright - Defense World
OnKure Therapeutics (OKUR): HC Wainwright & Co. Adjusts Price Ta - GuruFocus
H.C. Wainwright cuts OnKure stock price target to $27 on funding By Investing.com - Investing.com South Africa
H.C. Wainwright cuts OnKure stock price target to $27 on funding - Investing.com
Wall Street Zen Upgrades OnKure Therapeutics (NASDAQ:OKUR) to Hold - Defense World
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
OnKure Therapeutics, Inc. 2025 Annual Report: Precision Oncology Pipeline and Focus on PI3Kα Inhibitors - Minichart
Onkure Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Breast cancer trial data and $59M cash: inside OnKure's 2026 pipeline plans - Stock Titan
OnKure Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Can OnKure Therapeutics Inc deliver consistent EPS growth2025 Market Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Onkure Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
OKUR PE Ratio & Valuation, Is OKUR Overvalued - Intellectia AI
Pullback Watch: What is the PEG ratio of OnKure Therapeutics IncJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Why OnKure Therapeutics Inc. stock appeals to dividend seekersWeekly Investment Recap & Expert Approved Trade Ideas - mfd.ru
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 43.6% in January - Defense World
Is OnKure Therapeutics Inc. stock oversold or undervaluedJuly 2025 Rallies & Community Trade Idea Sharing Platform - mfd.ru
EV Market: Should I set a stop loss on OnKure Therapeutics Inc2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Is OnKure Therapeutics Inc. in a bullish channelJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
Top Entero Therapeutics (GRDX) Competitors 2026 - MarketBeat
Published on: 2026-01-29 15:39:37 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Why OnKure Therapeutics Inc. stock could be next big winnerShort Interest Overview & High Yield Trading Alerts - bollywoodhelpline.com
Analyzing Nautilus Biotechnology (NASDAQ:NAUT) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts - Defense World
Published on: 2026-01-11 10:53:08 - Улправда
Targets Report: How risky is OnKure Therapeutics Inc stock nowEarnings Recap Summary & Weekly Sector Rotation Insights - Bộ Nội Vụ
How OnKure Therapeutics Inc. stock performs in weak economyEarnings Overview Report & Daily Market Momentum Tracking - Улправда
Geopolitics Watch: How risky is OnKure Therapeutics Inc. stock nowMarket Sentiment Review & Detailed Earnings Play Strategies - Улправда
Bear Alert: Will OnKure Therapeutics Inc stock attract ESG investorsFed Meeting & Weekly High Momentum Picks - Bộ Nội Vụ
Rally Mode: Why OnKure Therapeutics Inc. stock could be next big winnerJuly 2025 Snapshot & Safe Entry Trade Reports - Улправда
How OnKure Therapeutics Inc. stock performs after earnings - ulpravda.ru
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com India
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):